Is Empagliflozin safe while breastfeeding?
Here is what LactMed, the Drugs and Lactation Database published by the U.S. National Institute of Child Health and Human Development (NICHD), reports about Empagliflozin. The text below is quoted from that source — it is not our own verdict.
Summary of use during breastfeeding
Little information is available on the clinical use of empagliflozin during breastfeeding. Empagliflozin is an uncharged molecule that is 86% protein bound in plasma, so it is unlikely to pass into breastmilk in clinically important amounts. The manufacturer does not recommend empagliflozin during breastfeeding because of a theoretical risk to the infant's developing kidney. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Effects on the breastfed infant
A mother with glycogen storage disease type Ib was taking empagliflozin 20 mg daily during pregnancy and postpartum. Breastfeeding (extent and duration not stated) was successfully initiated, and the infant showed normal development at 3 months of age.[1]
Effects on milk supply
Relevant published information was not found as of the revision date.
Levels in milk
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Alternatives LactMed lists
Empagliflozin in pregnancy
LactMed covers breastfeeding only. For what the NHS and the US prescribing label say about pregnancy, see:
Source: Drugs and Lactation Database (LactMed), National Institute of Child Health and Human Development (NICHD), via NCBI Bookshelf, record “Empagliflozin” (LM1376). LactMed on NCBI Bookshelf. LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Educational summary of an authoritative source — not medical advice. Never start, stop, or change a medicine while breastfeeding without confirming with your doctor.